IL86278A - Endowing cells with antibody specificity using chimeric t cell receptor - Google Patents

Endowing cells with antibody specificity using chimeric t cell receptor

Info

Publication number
IL86278A
IL86278A IL8627888A IL8627888A IL86278A IL 86278 A IL86278 A IL 86278A IL 8627888 A IL8627888 A IL 8627888A IL 8627888 A IL8627888 A IL 8627888A IL 86278 A IL86278 A IL 86278A
Authority
IL
Israel
Prior art keywords
antigens
gene pairs
gene
cells
cell receptor
Prior art date
Application number
IL8627888A
Other languages
English (en)
Other versions
IL86278A0 (en
Inventor
Zelig Eshhar
Gideon Gross
Tova Waks
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL8627888A priority Critical patent/IL86278A/xx
Publication of IL86278A0 publication Critical patent/IL86278A0/xx
Priority to JP1113577A priority patent/JP3001208B2/ja
Priority to AU34012/89A priority patent/AU3401289A/en
Priority to CA000598635A priority patent/CA1338570C/en
Priority to ES89108162T priority patent/ES2088873T3/es
Priority to AT89108162T priority patent/ATE127153T1/de
Priority to EP89108162A priority patent/EP0340793B1/en
Priority to DE68923990T priority patent/DE68923990T2/de
Priority to US08/055,396 priority patent/US5906936A/en
Priority to US08/474,819 priority patent/US5912172A/en
Priority to GR950402751T priority patent/GR3017638T3/el
Publication of IL86278A publication Critical patent/IL86278A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL8627888A 1988-05-04 1988-05-04 Endowing cells with antibody specificity using chimeric t cell receptor IL86278A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL8627888A IL86278A (en) 1988-05-04 1988-05-04 Endowing cells with antibody specificity using chimeric t cell receptor
JP1113577A JP3001208B2 (ja) 1988-05-04 1989-05-02 組換え体遺伝子対
AU34012/89A AU3401289A (en) 1988-05-04 1989-05-03 Endowing cells with antibody specificity
CA000598635A CA1338570C (en) 1988-05-04 1989-05-03 Endowing cells with antibody specificity
DE68923990T DE68923990T2 (de) 1988-05-04 1989-05-05 Zellen mit ausgestattener Antikörperspezifität.
ES89108162T ES2088873T3 (es) 1988-05-04 1989-05-05 Celulas dotadas con especialidad de anticuerpos.
AT89108162T ATE127153T1 (de) 1988-05-04 1989-05-05 Zellen mit ausgestattener antikörperspezifität.
EP89108162A EP0340793B1 (en) 1988-05-04 1989-05-05 Endowing cells with antibody specificity
US08/055,396 US5906936A (en) 1988-05-04 1993-05-04 Endowing lymphocytes with antibody specificity
US08/474,819 US5912172A (en) 1988-05-04 1995-06-07 Endowing lymphocytes with antibody specificity
GR950402751T GR3017638T3 (en) 1988-05-04 1995-10-04 Endowing cells with antibody specificity.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8627888A IL86278A (en) 1988-05-04 1988-05-04 Endowing cells with antibody specificity using chimeric t cell receptor

Publications (2)

Publication Number Publication Date
IL86278A0 IL86278A0 (en) 1988-11-15
IL86278A true IL86278A (en) 2003-06-24

Family

ID=11058801

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8627888A IL86278A (en) 1988-05-04 1988-05-04 Endowing cells with antibody specificity using chimeric t cell receptor

Country Status (9)

Country Link
EP (1) EP0340793B1 (xx)
JP (1) JP3001208B2 (xx)
AT (1) ATE127153T1 (xx)
AU (1) AU3401289A (xx)
CA (1) CA1338570C (xx)
DE (1) DE68923990T2 (xx)
ES (1) ES2088873T3 (xx)
GR (1) GR3017638T3 (xx)
IL (1) IL86278A (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0527199T4 (da) * 1990-05-01 2000-12-04 Univ Leland Stanford Junior Præparater til anvendelse ved en fremgangsmåde tilbehandling af et menneske, der lider afdissemineret sclerose
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
FR2672901B1 (fr) * 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
FR2676069B1 (fr) * 1991-05-02 1994-09-09 Imnunotech Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vbeta2 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
JPH0543598A (ja) * 1991-08-15 1993-02-23 Hajime Nishimura 免疫グロブリンの抗原認識領域を含むハイブリツド蛋白質受容体、その製造方法およびそれを用いる抗原測定法
FR2681875A1 (fr) * 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
JP3875730B2 (ja) * 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
ATE178348T1 (de) * 1993-12-01 1999-04-15 Ausimont Spa Schmierfette auf basis von wasserstoffenthaltenden mineral- oder syntheseölen mit verbesserten eigenschaften
US7354587B1 (en) 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US7723111B2 (en) 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
CA2734265C (en) 2008-08-20 2017-12-19 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T3 (es) 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
EP3193592A1 (en) * 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CN115927191A (zh) 2015-10-23 2023-04-07 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
JP2020500530A (ja) * 2016-12-02 2020-01-16 ユニバーシティ オブ サザン カリフォルニア 合成免疫受容体およびその使用方法
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
IL310182A (en) * 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures of chimeric antibody/T-cell receptor and uses thereof
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
BR112022018491A2 (pt) 2020-03-20 2022-11-29 Lyell Immunopharma Inc Marcadores de superfície celular recombinante
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
EP4298208A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Methods for culturing cells
WO2023070041A1 (en) 2021-10-21 2023-04-27 Lyell Immunopharma, Inc. Enhanced immune cell therapy
US20230181644A1 (en) 2021-10-28 2023-06-15 Lyell Immunopharma, Inc. Methods of generating cells
AU2022379192A1 (en) 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
CA3234822A1 (en) 2021-10-28 2023-05-04 Suman Kumar VODNALA Methods for culturing cells expressing ror1-binding protein
WO2023133540A1 (en) 2022-01-07 2023-07-13 Lyell Immunopharma, Inc. Il-12 affinity variants
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins

Also Published As

Publication number Publication date
ATE127153T1 (de) 1995-09-15
EP0340793A3 (en) 1991-02-27
GR3017638T3 (en) 1996-01-31
ES2088873T3 (es) 1996-10-01
IL86278A0 (en) 1988-11-15
DE68923990T2 (de) 1996-02-08
CA1338570C (en) 1996-09-03
AU3401289A (en) 1989-11-09
JP3001208B2 (ja) 2000-01-24
EP0340793B1 (en) 1995-08-30
DE68923990D1 (de) 1995-10-05
EP0340793A2 (en) 1989-11-08
JPH02174681A (ja) 1990-07-06

Similar Documents

Publication Publication Date Title
IL86278A (en) Endowing cells with antibody specificity using chimeric t cell receptor
Zurawski Jr et al. Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines
EP0352761A3 (de) Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung
ATE229342T1 (de) Verwendung von interleukin-15
IL142905A0 (en) Functional antagonists of hedgehog activity
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
KR920703635A (ko) 가용성 단일 사슬 t세포 수용체
EP1009752A4 (en) NOVEL TANGO-77 PROTEIN FAMILY MOLECULES AND USES THEREOF
EP0759942A4 (en) INTERLEUKIN-15 RECEPTORS
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
DE69535789D1 (de) Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen
Dervillez et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV‐1 fusion inhibitory peptide C46
KR920012440A (ko) 인간 인터류킨-5 수용체
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
GR3034176T3 (en) Recombinant DNA coding for a T-cell receptor chain, process for preparation and antibodies and pharmaceutical compositions comprising the same.
HUP9801062A2 (hu) Új PKA-kötődő fehérjék, és ezek alkalmazása
KR890013177A (ko) 신규폴리펩티드 및 그것을 코우드하는 dna
WO2001014414A3 (en) Human abc2 transporter and uses thereof
Lunney et al. Interspecies Cross Reactivity of Monoclonal Anti-IE Antibodies Specific for Polymorphic Ia Determinants
Fleischer et al. Molecular associations required for signalling via dipeptidyl peptidase IV (CD26)
Denaro et al. Expression of xenogeneic MHC class II molecules in HLA‐DR+ and‐DR–cells: influence of retrovirus vector design and cellular context
Marchalonis et al. Introduction—The Immunoglobulin-Like T Cell Receptor Problem

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees